# Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)

> **NCT06575595** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Tulisokibart

## Key facts

- **NCT ID:** NCT06575595
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-24
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06575595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06575595, "Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06575595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*